1	Type 1 and type 2 diabetes mellitus: Clinical outcomes due to COVID-19.
2	Protocol of a systematic literature review.
3	Type 1 and type 2 diabetes in COVID-19. Systematic review protocol
4	Juan Pablo Pérez Bedoya ^{1¶,#a} , Alejandro Mejía Muñoz ^{2¶} , Noël Christopher
5	Barengo ^{3&} , Paula Andrea Diaz Valencia ^{1&} .
6	¹ Epidemiology Group. National Faculty of Public Health, University of Antioquia,
7	Medellín, Colombia.
8	² Biology and control of infectious diseases group. Faculty of exact and natural
9	sciences, University of Antioquia, Medellín, Colombia.
10	³ Associate professor. Department of Translational Medicine, Herbert Wertheim
11	College of Medicine & Department of Global Health, Robert Stempel College of
12	Public Health and Social Work, Florida International University, Miami, FL, USA.
13	#a Current Address: University of Antioquia. National Faculty of Public Health:
14	Street. 62 #52-59, Medellin, Antioquia.
15	
16	* Corresponding author
17	E-mail: juan.perez42@udea.edu.co (JPPB)
18	
19	[¶] These authors contributed equally to this work
20	^{&} These authors also contributed equally this work

21 Abstract

22 Introduction

Diabetes has been associated with an increased risk of complications in patients with COVID-19. Most studies do not differentiate between patients with type 1 and type 2 diabetes, which correspond to two pathophysiological distinct diseases that could represent different degrees of clinical compromise.

27 **Objective**

To identify if there are differences in the clinical outcomes of patients with COVID-19 and diabetes (type 1 and type 2) compared to patients with COVID-19 without diabetes.

31 Methods

Observational studies of patients with COVID-19 and diabetes (both type 1 and 32 33 type 2) will be included without restriction of geographic region, gender or age, whose outcome is hospitalization, admission to intensive care unit or mortality 34 compared to patients without diabetes. Two authors will independently perform 35 36 selection, data extraction, and quality assessment, and a third reviewer will resolve discrepancies. The data will be synthesized regarding the sociodemographic and 37 clinical characteristics of patients with diabetes and without diabetes accompanied 38 by the measure of association for the outcomes. The data will be synthesized 39 40 regarding the sociodemographic and clinical characteristics of patients with

diabetes and without diabetes accompanied by the measure of association for theoutcomes.

43 **Expected results**

Update the evidence regarding the risk of complications in diabetic patients with COVID-19 and in turn synthesize the information available regarding type 1 and type 2 diabetes mellitus, to provide keys to a better understanding of the pathophysiology of diabetics.

48 Systematic review registry

This study was registered at the International Prospective Registry for Systematic
Reviews (PROSPERO) - CRD42021231942.

E	1
J	Т

52

53

54

55

57 Introduction

The Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2), the 58 causal viral agent of coronavirus disease 2019 (COVID-19), currently has the world 59 in one of the greatest public health crises of recent times since its appearance at 60 61 the end of 2019 in the city of Wuhan, China [1]. The infection has a mild or even asymptomatic course in most cases, but in elderly patients (over 60 years-of-age) 62 and in those with pre-existing chronic comorbidities, it can progress severe 63 complications such as pneumonia, acute respiratory distress (ARDS) with 64 hyperinflammatory involvement and multi-organ failure, leading in some cases to 65 death [2]. 66

67 Different studies have reported that patients diagnosed with diabetes who suffer from COVID-19 disease have higher morbidity and mortality compared with people 68 69 without diabetes [3]. An analysis by Gude Sampedro et al using prognostic models found that diabetic patients had greater odds of being hospitalized (OR 1.43; 95% 70 71 CI: 1.18 to 1.73), admitted to the intensive care unit (OR 1.61; 95% CI: 1.12 to 72 2.31) and dying from COVID-19 (OR 1.79; 95% CI %: 1.38 to 2.32) compared with 73 patients without diabetes [4]. However, it is difficult to establish whether diabetes alone directly contributed to the increase likelihood of complications. 74

Several studies using secondary data have emerged during the course of the pandemic that seek to determine the association of diabetes with mortality and other clinical outcomes in patients with COVID-19, such as, for example, a metaanalysis carried out by Shang et al. of severe infection and mortality from COVID-

79 19 in diabetic patients compared with those without diabetes. They reported that patients with COVID-19 and diabetes had higher odds of serious infection (OR = 80 2.38, 95% CI: 2.05 to 2.78) and mortality (OR = 2, 21, 95% CI: 1.83 to 2.66) than 81 patients without diabetes [5]. Despite the fact that there are several primary studies 82 that attempt to explain the association between diabetes and COVID-19, most 83 studies lack epidemiological rigor in the design and methodology used [6]. In 84 85 addition, many of them did not distinguish between type 1 and type 2 diabetes, which are two very different conditions with different clinical development and 86 pathophysiological mechanisms [7]. This may lead to different degrees of clinical 87 88 complications from COVID-19. Currently, there is a gap in knowledge about the complications in patients with COVID-19 according to the type of diabetes. 89 Moreover, only limited information exist how COVID-19 affects type 1 patients 90 [8,9]. 91

The objective of this systematic literature review will be to identify whether there are differences in the clinical outcomes of both type 1 and type 2 diabetes patients diagnosed with COVID-19 compared with patients with COVID-19 without a diagnosis of diabetes. This study will provide scientific evidence regarding the risk of complications in diabetic patients with COVID-19 and, in turn, synthesize the available information regarding to type 1 and type 2 diabetes.

98 Methods/Design

99 Study design

This systematic literature review protocol was prepared according to the Preferred Reporting Elements for Systematic Review and Meta-Analysis Protocols (PRISMA-P) [10] (S1 Appendix). The results of the final systematic review will be reported according to the preferred reporting items for systematic reviews and metaanalyses (PRISMA 2020) [11,12]. In the event of significant deviations from this protocol, they will be reported and published with the results of the review.

Eligibility Criteria

107 **Participants (population)**

Patients with a confirmed diagnosis of COVID-19 without restriction of geographic 108 109 region, gender or age of the participants, in which the diagnostic algorithm used to confirm SARS-CoV-2 infection is adequately presented, as it is the case of 110 standardized molecular biology laboratory methods such as RT-PCR (real-time 111 112 reverse transcriptase polymerase chain reaction) and/or antigen test for the detection of virus surface proteins, or failing that, diagnosis clinical or 113 114 epidemiological based on international guidelines and recommendations by the WHO or/and the Center for Disease Control and Prevention (CDC). 115

116 **Exposure**

Patients with COVID-19 and concomitant diagnosis of unspecified diabetes
mellitus, differentiated into type 1 diabetes mellitus or type 2 diabetes mellitus,
without restriction of geographic region, gender, or age of the patients, who present

- definition of clinical criteria and /or paraclinical tests used by researchers to classify
- 121 patients according to their diabetes status.

122 **Comparator**

Patients with COVID-19 who do not have a concomitant diagnosis of diabetesmellitus.

125 **Outcome**

The main endpoint is all-cause mortality (according to the definitions of each primary study) and the secondary outcomes are hospitalization and admission to the ICU, where the authors specify a clear definition based on clinical practice guidelines and provide a well-defined criteria for patient outcomes.

130 **Type of study**

Primary observational original research studies (prospective or retrospective
cohort, case-control design, and cross-sectional studies) will be included in this
systematic review.

134 **Exclusion criteria**

135 Clinical trials, editorials, letters to the editor, reviews, case reports, case series, 136 narrative reviews or systematic reviews and meta-analyses, as well as research in 137 the field of basic sciences based on experimental laboratory models, will be 138 excluded. Similarly, original research articles that only include other types of 139 diabetes such as monogenic diabetes, gestational diabetes, latent autoimmune

diabetes in adults, ketosis-prone diabetes, among others, or articles with a
publication status prior to review will be excluded.

142 Information sources and search strategy

143 For the preparation of the search strategy, the recommendations of the PRISMA-S 144 guide [13] will be adopted. Relevant articles will be identified by electronic search 145 applying the equation previously developed by the researchers and validated by an 146 expert librarian (S2 Appendix). The following electronic bibliographic databases will 147 be used: MEDLINE, EMBASE, LILACS, OVID MEDLINE and WHO (COVID-19 148 Global literature on coronavirus disease) with a publication date from December 149 2019 to March 20, 2022, without language restriction. To identify other potentially 150 eligible studies, the references of relevant publications will be reviewed to perform a snowball manual search. 151

152 Study selection process

Two investigators will independently assess all the titles and abstracts of the 153 retrieved articles using the free access Rayvan software® [14]. Disagreement will 154 be resolved in the first instance through discussion and in a second instance 155 156 through a third reviewer. Articles that meet the eligibility criteria will be included. 157 The full text will be read independently by two researchers. Discrepancies will be resolved through discussion or a third reviewer. The process of identification, 158 159 screening and inclusion of primary studies will be described and presented using the flow chart recommended by the PRISMA statement in its latest version 2020 160 [11,12]. 161

Data collection and extraction

Standardized and validated forms will be used to collect the data extracted from 163 164 the primary studies, accompanied by a detailed instruction manual to specify the guiding questions, and avoid the introduction of bias. This process will be carried 165 out by two researchers independently. A third investigator will verify the extracted 166 167 data to ensure the accuracy of the records. The authors of the primary studies will be contacted to resolve any questions that may arise. The reviewers will resolve 168 169 disagreements through discussion and one of the two referees will adjudicate the discrepancies presented through discussion and consensus. 170

171 In specific terms, the following data will be collected both for the primary studies 172 that report diabetes and COVID-19 and for those that differentiate between DMT1 and DMT2: author, year and country where the study was carried out; study 173 design; general characteristics of the population, sample size, demographic data of 174 175 the participants (sex, age, ethnicity), percentage of patients with diabetes, percentage of patients with type 1 and/or type 2 diabetes, percentage of patients 176 without diabetes, frequency of comorbidities in diabetics and non-diabetics, 177 percentage of diabetic and non-diabetic patients who presented the outcomes 178 (hospitalization, ICU admission and mortality) and association measures reported 179 for the outcomes. Data extraction will be done using a Microsoft Excel 365 ® 180 181 spreadsheets.

182 Quality evaluation

The study quality assessment tool provided by the National Institutes of Health 183 184 (NIH) [15] will be used for observational studies such as cohort, case-control, and cross-sectional. Two tools will be sued: one for cohort and cross-sectional studies 185 (14 questions/domains) and one for case-control studies (12 questions/domains). 186 These tools are aimed at detecting elements that allow evaluation of possible 187 methodological problems, including sources of bias (for example, patient selection, 188 performance, attrition and detection), confounding, study power, the strength of 189 190 causality in the association between interventions and outcomes, among other factors. The different tools that will be used reflect a score of "1" or "0" depending 191 on the answer "yes" or "no", respectively for each question or domain evaluated, or 192 193 failing that, the indeterminate criterion option. For observational cohort studies, which consist of 14 risk of bias assessment domains, the studies will be classified 194 195 as having good quality if they obtain ≥ 10 points, of fair quality if they obtain 8 to 9 points, and of poor quality if they obtain less than 8 points. On the other hand, in 196 197 the case of case-control studies that consist of 12 bias risk assessment domains, 198 the studies will be classified as good quality if they obtained ≥ 8 points, regular quality if they obtained 6 to 7 points and of poor quality if they obtained less than 6 199 200 points. However, the internal discussion between the research team will always be considered as the primary quality criterion. 201

202 Data synthesis

A narrative synthesis with summary tables will be carried out according to the recommendations adapted from the Synthesis Without Meta-analysis (SWiM) quide to describe in a structured way the methods used, and the findings found in

the primary studies, as well as the criteria for grouping of the studies [16]. A narrative synthesis will be presented in two sections, one for patients with COVID-19 and diabetes and another for patients with COVID-19 and type 1 or type 2 diabetes.

Assessment of clinical and methodological heterogeneity will determine the 210 feasibility of the meta-analysis. Possible sources of heterogeneity identified are the 211 212 clinical characteristics of the study population, the criteria used to define the outcomes in the groups of patients, the time period of the pandemic in which the 213 study was carried out, and the availability of measurement and control for potential 214 confounding factors. For this reason, it is established a priori that this diversity of 215 216 findings will make it difficult to carry out an adequate meta-analysis [17]. However, if meta-analysis is considered feasible, the random effects model will be used due 217 to the high probability of heterogeneity between studies. Statistical heterogeneity 218 will be assessed using the X^2 test and the I^2 statistic, and publication bias 219 220 assessed using funnel plots if there are sufficient (>10) studies [18].

221 Exploratory ecological analysis

An exploratory ecological analysis of the association between the frequency of clinical outcomes of diabetic patients with COVID-19 and the indicators related to the health care dimension, reported for the different countries analyzed by means of the correlation coefficient, will be carried out. The open public databases of the World Bank (WB) [19], the World Health Organization (WHO) [20] and Our World In Data [21] will be used to extract population indicators related to health care,

among those prioritized, universal health coverage, hospital beds per 1,000
 people, doctors per 1,000 people, current health spending as a percentage of
 gross domestic product (GDP), percentage of complete vaccination coverage for
 COVID-19.

232 **Discussion**

Since the first epidemiological and clinical reports were released from the city of Wuhan regarding the clinical characteristics of patients with COVID-19, a high incidence of chronic non-communicable diseases has been observed in Covid-19 patients. Current scientific evidence has shown that certain comorbidities increase the risk for hospitalization, severity of illness or death from COVID-19, such as hypertension, cardiovascular disease, chronic kidney disease, chronic respiratory disease, diabetes, among others [22].

One of the main chronic comorbidities affected by the COVID-19 pandemic is diabetes. Multivariate analysis of several observational epidemiological studies have revealed that COVID-19 patients with diabetes were at increased risk of hospitalization, ICU admission, and mortality compared with patients without diabetes [4].

For this reason, it is expected that this systematic literature review will provide scientific support regarding the outcomes and complications that patients diagnosed with COVID-19 with type 1 or type 2 diabetes present compared with patients without diabetes. This information will be useful for healthcare personnel, public health professionals and epidemiologists involved in patient care or decision

making, generating epidemiological evidence. Thus, highlighting the decisive role of epidemiological research in the context of the pandemic, especially in the field of diabetes epidemiology may improve comprehensive management and care of diabetic patients. This study may also provide important information that can be used to update of clinical practice guidelines.

255 The status of the study

The study is in the selection phase of the records by applying the eligibility criteria to the titles and abstracts. Completion of the project is expected in September 2022 with the publication of the results.

259 **Conclusions**

This report describes the systematic review protocol that will be utilized to update the evidence regarding the risk of complications in diabetic patients with COVID-19 and in turn synthesize the information available regarding DM1 and DM2, to provide keys to a better understanding of the pathophysiology of diabetics.

264 Acknowledgments

This research was developed within the "Repository for the surveillance of risk factors for chronic diseases in Colombia, the Caribbean and the Americas" framework and financially supported by a grant of Colciencias 844 (grant number 111584467754).

269 **References**

Singhal T: A Review of Coronavirus Disease-2019 (COVID-19). Indian J
 Pediatr. 2020, 87:281-286. doi: 10.1007/s12098-020-03263-6.

- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
 infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395:497-
- 274 506. doi: 10.1016/S0140-6736(20)30183-5.
- Obukhov AG, Stevens BR, Prasad R, Li Calzi S, Boulton ME, Raizada MK, et
 al. SARS-CoV-2 Infections and ACE2: Clinical Outcomes Linked With
 Increased Morbidity and Mortality in Individuals With Diabetes. Diabetes. 2020,
 69:1875-1886. doi: 10.2337/dbi20-0019.
- 4. Gude-Sampedro F, Fernández-Merino C, Ferreiro L, Lado-Baleato Ó, 279 Espasandín-Domínguez J, Hervada X, et al. Development and validation of a 280 prognostic model based on comorbidities to predict COVID-19 severity: a 281 population-based study. Int J Epidemiol. 2021, 50:64-74. doi: 282 10.1093/ije/dyaa209. 283
- Shang L, Shao M, Guo Q, Shi J, Zhao Y, Xiaokereti J, et al. Diabetes Mellitus is
 Associated with Severe Infection and Mortality in Patients with COVID-19: A
 Systematic Review and Meta-analysis. Arch Med Res. 2020, 51:700-709. doi:
 10.1016/j.arcmed.2020.07.005.
- Selvin E, Juraschek SP: Diabetes Epidemiology in the COVID-19 Pandemic.
 Diabetes Care. 2020, 43:1690-1694. doi: 10.2337/dc20-1295.
- Gregory JM, Slaughter JC, Duffus SH, Smith TJ, LeStourgeon LM, Jaser SS, et
 al. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective
 Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes. Diabetes
 Care. 2021, 44:526-532. doi: 10.2337/dc20-2260.

294	8. Vamvini M, Lioutas VA, Middelbeek RJW. Characteristics and Diabetes Contro
295	in Adults With Type 1 Diabetes Admitted With COVID-19 Infection. Diabetes
296	Care. 2020, 43:e120-e122. doi: 10.2337/dc20-1540.
297	9. Ebekozien OA, Noor N, Gallagher MP, Alonso GT. Type 1 Diabetes and

- 298 COVID-19: Preliminary Findings From a Multicenter Surveillance Study in the
- U.S. Diabetes Care. 2020, 43:e83-e85. doi: 10.2337/dc20-1088.
- 10. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al.
 Preferred reporting items for systematic review and meta-analysis protocols
 (PRISMA-P) 2015 statement. Syst Rev. 2015, 4:1-9. doi: 10.1186/2046-4053-4 1.
- 11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et
 al. The PRISMA 2020 statement: An updated guideline for reporting systematic
 reviews . PLoS Med. 2021, 18:1-15. doi: 10.1371/journal.pmed.1003583.
- 12. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.

308 PRISMA 2020 explanation and elaboration: updated guidance and exemplars

for reporting systematic reviews. BMJ. 2021, 372:1-36. doi: 10.1136/bmj.n160.

13. Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al. 310 PRISMA-S: an extension to the PRISMA Statement for Reporting Literature 311 Searches Systematic 312 in Reviews. Syst Rev. 2021, 10:1-19. doi: 10.1186/s13643-020-01542-z. 313

14. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and
mobile app for systematic reviews. Syst Rev. 2016, 5:1-10. doi:
10.1186/s13643-016-0384-4.

317	15. National Institutes of Health (NIH) [Internet]. Study Quality Assessment Tools;
318	2021. [cited 16 June 2022]. Available at: https://www.nhlbi.nih.gov/health-
319	topics/study-quality-assessment-tools.

- 16. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et
- al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting
- 322 guideline. BMJ. 2020, 368:1-6. doi: 10.1136/bmj.l6890.
- 17. Cochrane Handbook for Systematic Reviews of Interventions; 2022. [cited 16
 June 2022]. Available at: https://training.cochrane.org/handbook/current.
- 18. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing
- heterogeneity in meta-analysis: Q statistic or I2 index?. Psychol Methods. 2006,
- 327 11:193-206. doi: 10.1037/1082-989X.11.2.193.
- 19. World Bank Group [Internet]. World Bank Indicators; 2022. [cited 16 June
 2022]. Available at: https://datos.bancomundial.org/indicador.
- 20. World Health Organization (WHO) [Internet]. Global Health Observatory Data
 Repository; 2021. [cited 16 June 2022]. Available at:
 https://apps.who.int/gho/data/node.home.
- 21. Our World In Data [Internet]. Statistics and Research Coronavirus Pandemic
 (COVID-19); 2022. [cited 16 June 2022]. Available at:
 https://ourworldindata.org/coronavirus.
- 22. Centers for Disease Control and Prevention [Internet]. COVID-19. People with
- 337 Certain Medical Conditions; 2021. [cited 16 June 2022]. Available at:
- 338 https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-
- 339 with-medical-conditions.html?CDC_AA_refVal=ht....

Supporting information

- 341 S1 Appendix. PRISMA-P (Preferred Reporting Items for Systematic review and
- 342 Meta-Analysis Protocols) 2015 checklist: Recommended items to address in a
- 343 systematic review protocol.
- 344 **S2 Appendix**. Search string details for each database.